Current issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer

Sung Gwe Ahn, Joon Jeong, Soon Won Hong, Woo Hee Jung

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)


With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value and the potential for predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been established. In this article, we review current issues and clinical evidence for the use of TILs in breast cancer.

Original languageEnglish
Pages (from-to)355-363
Number of pages9
JournalJournal of Pathology and Translational Medicine
Issue number5
Publication statusPublished - 2015

Bibliographical note

Publisher Copyright:
© 2015 The Korean Society of Pathologists/The Korean Society for Cytopathology.

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology


Dive into the research topics of 'Current issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer'. Together they form a unique fingerprint.

Cite this